Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference29 articles.
1. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biology Evaluation and Research. Enhancing the Diversity of Clinical Trial Populations—Eligibility Criteria, Enrollment Practices, and Trial Designs. Guidance for Industry (2022); https://www.fda.gov/media/127712/download
2. Li, B. T. et al. Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition. Nat. Med. 28, 620–626 (2022).
3. Liu, S. M. et al. Biomarker-driven studies with multi-targets and multi-drugs by next-generation sequencing for patients with non-small-cell lung cancer: an open-label, multi-center, phase II adaptive umbrella trial and a real-world observational study (CTONG1702&CTONG1705). Clin. Lung Cancer 23, e395–e399 (2022).
4. Real-world evidence. US Food and Drug Administration https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence (2022).
5. Stephens, P. et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525–526 (2004).
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献